• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Chronic Disease

Combination chemotherapy associated with improved survival in refractory colorectal cancer [RECOURSE]

byMatthew Growdon
May 14, 2015
in Chronic Disease, Gastroenterology, Oncology
Reading Time: 3 mins read
0
Share on FacebookShare on Twitter

1. TAS-102 is a combination of a thymidine-based nucleic acid analogue, trifluridine, and a thymidine phosphorylase inhibitor, tipiracil hydrochloride.

2. Patients with refractory colorectal cancer treated with TAS-102 had significantly improved median overall survival compared to patients treated with placebo; neutropenia and leukopenia were seen in 38% and 21% of the TAS-102 treated patients, respectively.

Evidence Rating Level: 1 (Excellent)

Study Rundown: The contemporary standard chemotherapy regimen for metastatic colorectal cancer (CRC) is a combination of fluorouracil and leukovorin, irinotecan or oxaliplatin, and either bevacizumab or an epidermal growth factor inhibitor. Ongoing research seeks to elucidate agents that can serve in cases of metastatic CRC that are refractory despite these treatments. One such agent is TAS-102, a combination of a thymidine-based nucleic acid analogue, trifluridine, and a thymidine phosphorylase inhibitor, tipiracil hydrochloride. In previous phase 1 and 2 clinical studies, this agent showed promise in the treatment of refractory CRC.

In this multinational, phase 3 randomized placebo-controlled trial, 800 patients with metastatic CRC refractory to standard therapies received TAS-102 or placebo. Patients had previously undergone treatment within multiple rounds of standard chemotherapies or had experienced clinically significant side effects from standard therapy that precluded being treated again. In a survival analysis, the median overall survival in the TAS-102 group was 7.1 months compared to 5.3 months in the placebo group; a significant improvement was also noted in overall progression-free survival and median time to worsening performance status. Common adverse effects associated with treatment with TAS-102 included neutropenia (38%) and leukopenia (21%); febrile neutropenia occurred in 4% of patients treated with TAS-102 and was associated with death due to sepsis in one case.

This drug-company-sponsored randomized, controlled trial provides solid grounding that TAS-102 provides benefit in the treatment of refractory CRC, though treatment must be weighed against the associated side effect profile. Of note, this finding was consistent across patients regardless of KRAS mutation tumor status, but insufficient tumor specimens were assessed for BRAF status to test within this subgroup.

Click to read the study, published today in NEJM

RELATED REPORTS

Shortened duration of adjuvant chemotherapy in individuals with stage III colon cancer may be associated with noninferior overall survival

#VisualAbstract: Pembrolizumab linked to longer cancer-free period in advanced MSI-H-dMMR colorectal cancer

Addition of bevacizumab to standard therapy improves outcomes in metastatic colorectal cancer

Relevant Reading: Systemic Therapy for Colorectal Cancer

In-Depth [randomized controlled trial]: This multinational phase 3 randomized, placebo-controlled trial involved 800 patients with metastatic CRC refractory to standard therapies who received TAS-102 or placebo. Patients were required to have adequate bone-marrow, liver, and renal function, and to have a Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 (indicating either no symptoms or mild symptoms). Patients were randomized in a 2:1 ratio to receive TAS-102 or placebo. In the primary outcome analysis, patients with TAS-102 had a median overall survival of 7.1 months compared to 5.3 months in the placebo group (HR for death, 0.68, 95% CI, 0.58 to 0.81, P<0.001); this finding was consistent across almost all subgroup analyses. The hazard ratio for progression or death for TAS-102 versus placebo was 0.48 (95%CI, 0.41-0.57, P<0.001), which was also consistent across subgroup analyses (including KRAS genotype, age, geographic region, gender, ECOG performance status, and prior treatment characteristics). Serious adverse events occurred in 30% of those treated with TAS-102 compared to 34% of those in the placebo arm. 38% of those receiving TAS-102 experienced neutropenia of grade 3 or higher, 4% had febrile neutropenia (1 case associated with sepsis and death), and 9% received granulocyte colony-stimulating factor.

Image: PD

©2015 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: colon cancer
Previous Post

HPV vaccinations for boys can increase benefits of vaccination program

Next Post

Weakened grip strength associated with increased morbidity and mortality [PURE study]

RelatedReports

Racial differences in colorectal cancer survival linked to health at initial diagnosis
2 Minute Medicine

Shortened duration of adjuvant chemotherapy in individuals with stage III colon cancer may be associated with noninferior overall survival

June 2, 2021
#VisualAbstract: Occult Blood in Feces Is Associated With an Increased Risk of Ischemic Stroke and Myocardial Infarction
Chronic Disease

#VisualAbstract: Pembrolizumab linked to longer cancer-free period in advanced MSI-H-dMMR colorectal cancer

January 28, 2021
Radiofrequency ablation of hepatic metastases in colorectal cancer linked with improved survival
Gastroenterology

Addition of bevacizumab to standard therapy improves outcomes in metastatic colorectal cancer

August 31, 2020
Quick Take: Diagnostic Yield of One-Time Colonoscopy vs One-Time Flexible Sigmoidoscopy vs Multiple Rounds of Mailed Fecal Immunohistochemical Tests in Colorectal Cancer Screening
Chronic Disease

Quick Take: Efficacy and Long-term Peripheral Sensory Neuropathy of 3 vs 6 Months of Oxaliplatin-Based Adjuvant Chemotherapy for Colon Cancer

September 25, 2019
Next Post
Weakened grip strength associated with increased morbidity and mortality [PURE study]

Weakened grip strength associated with increased morbidity and mortality [PURE study]

Record-based algorithm may improve lung cancer screening follow-up

Record-based algorithm may improve lung cancer screening follow-up

Endoscopic screening for esophageal cancer may reduce long-term mortality

Endoscopic screening for esophageal cancer may reduce long-term mortality

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

Get 2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Pelvic lymph node radiotherapy and androgen deprivation therapy augment progression-free status following prostatectomy
  • Operating the day after performing surgery the previous night not associated with adverse patient outcomes
  • Gratitude-focused writing may improve mental wellness during periods of chronic stress
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.